Skip to main content
. 2018 Sep 10;11:506. doi: 10.1186/s13071-018-3083-2

Table 5.

Individual lesion and extent scores (Day 0 and Day 84) for 31 dogs treated with afoxolaner who didn’t received concomitant medications for the control of skin conditions

Lesion Severity Extent
Day 0 Day 84 Day 0 Day 84
Alopecia Absent (%) 0 78.1 Absent (%) 0 78.1
Mild (%) 18.2 18.8 Limited (%)a 54.5 21.9
Moderate (%) 33.3 3.1 Marked (%)b 39.4 0
Severe (%) 48.5 0 Generalised (%)c 6.1 0
CMH row mean scores differ F(1, 63) = 46.7; P <0.0001 CMH row mean scores differ F(1, 63) = 42.3; P <0.0001
Erythema Absent (%) 12.1 87.5 Absent (%) 12.1 87.5
Mild (%) 18.2 9.4 Limited (%)a 51.5 12.5
Moderate (%) 24.2 3.1 Marked (%)b 27.3 0
Severe (%) 45.5 0 Generalised (%)c 9.1 0
CMH row mean scores differ F(1, 63) = 38.1; P <0.0001 CMH row mean scores differ F(1, 63) = 36.3; P <0.0001
Papules Absent (%) 53.1 93.8 Absent (%) 53.1 93.8
Mild (%) 12.5 3.1 Limited (%)a 25.0 6.3
Moderate (%) 12.5 3.1 Marked (%)b 21.9 0
Severe (%) 21.9 0 Generalised (%)c 0 0
CMH row mean scores differ F(1, 62) = 13.8; P = 0.0002 CMH row mean scores differ F(1, 62) = 13.9; P = 0.0001
Pustules Absent (%) 56.3 96.9 Absent (%) 56.3 96.9
Mild (%) 12.5 0 Limited (%)a 21.9 3.1
Moderate (%) 18.8 3.1 Marked (%)b 21.9 0
Severe (%) 12.5 0 Generalised (%)c 0 0
CMH row mean scores differ F(1, 62) = 14.2; P = 0.0002 CMH row mean scores differ F(1, 62) = 14.7; P = 0.0001
Scaling crusts Absent (%) 39.4 96.9 Absent (%) 21.2 93.8
Mild (%) 15.2 3.1 Limited (%)a 51.5 6.3
Moderate (%) 24.2 0 Marked (%)b 21.2 0
Severe (%) 0 0 Generalised (%)c 6.1 0
CMH row mean scores differ F(1, 63) = 32.1; P <0.0001 CMH row mean scores differ F(1, 63) = 33.5; P <0.0001

Note: 17 animals were excluded from the analyses because of concomitant medications for the control of skin conditions

aSeen on 1/3 of the (head + body) surface

bSeen on 2/3 of the (head + body) surface

cSeen all over the head + body